不良研究所

Focus

Marcel Behr was the Founding Director of the 不良研究所 International TB Centre. He completed a BSc in听Biochemistry at the University of Toronto, an MD at Queen鈥檚 University and residency training in Internal Medicine, Infectious Diseases and Medical Microbiology at 不良研究所. He also completed an MSc in Epidemiology and Biostatistics at 不良研究所听and then did post-doctoral training in molecular epidemiology and bacterial genomics, with Peter Small, at Stanford University. He is currently a Professor of Medicine at 不良研究所 and Associate Director of the Infectious Diseases and Immunity in Global Health Program at the Research Institute of the 不良研究所 Health Centre (). In听addition to research activities, he attends on the Infectious Diseases consult service, he works in the TB clinic of the MUHC and he directs the mycobacteriology laboratory of the OptiLab Grappe-CUSM.

Marcel鈥檚 research employs genomic methods to study the epidemiology and pathogenesis of听TB and other mycobacterial infections. His research is supported by a Foundation Grant听from the CIHR and he also enjoys an active collaboration with the Structure-Based Drug Discovery Coalition () for the development of novel anti-mycobacterial treatments. He has published more than 200 peer-reviewed publications, reviews and book chapters. In recognition of his work, he has been elected to the American Society of Clinical Investigation and is a Fellow of听the Canadian Academy of Health Sciences, the Royal Society of Canada and the American Academy of Microbiology.

Keywords

Tuberculosis, BCG, molecular microbiology, genomics, molecular epidemiology, non-tuberculous mycobacteria, NOD2, N-glycolyl muramyl dipeptide

Selected Publications

• Pai M, Behr MA, Dowdy D,听Djedda K, Divangahi M, Boehme C, Ginsberg A, Swaminathan S, Spigelman M, Getahun H, Menzies D, Raviglione M. Tuberculosis. Nature Reviews Disease Primers 2016 Oct 27;2:16076. doi:10.1038/nrdp.2016.76

• 听Behr MA, Edelstein P, Ramakrishnan L. Revisiting timetable of tuberculosis. BMJ. 2018 Aug 23;362:k2738. doi: 10.1136/bmj.k2738.

• 听Duffy SC, Srinivasan S, Schilling MA, Stuber T, Danchuk SN, Michael JS, Venkatesan M, Bansal N, Maan S, Jindal N, Chaudhary D, Dandapat P, Katani R, Chothe S, Veerasami M, Robbe-Austerman S, Juleff N, Kapur V, Behr MA. Reconsidering Mycobacterium bovis as a proxy for zoonotic tuberculosis: a molecular epidemiological surveillance study. Lancet Microbe. 2020 Jun;1(2):e66-e73. doi: 10.1016/S2666-5247(20)30038-0.

• 听Ghanem M, Dube J-Y, Wang J, McIntosh F, Houle D, Domenech P, Reed MB, Raman S, Buter J, Minnaard AJ, Moody DB, Behr MA. Heterologous production of 1-tuberculosinyladenosine in Mycobacterium kansasii models pathoevolution towards the transcellular lifestyle of Mycobacterium tuberculosis. mBio. 2020 Oct 20;11(5):e02645-20. doi: 10.1128/mBio.02645-20.

• 听Sullivan J, Lupien A, Kalthoff E, Hamela C, Taylor L, Munro K, Schmeing M, Kremer L, Behr AM. Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline. PLoS Pathog. 2021 Oct 12;17(10):e1009965. doi:10.1371/journal.ppat.1009965.

External Links

• Lab Website